
Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Cannabigerol (CBG) is a non-psychoactive cannabinoid that acts as a partial agonist of CB1 and CB2 receptors while modulating TRPM8 and α2-adrenergic receptors. CBG demonstrates neuroprotective, anti-inflammatory, and intraocular pressure-reducing properties through multiple molecular pathways.

Reported Benefits (Provisional)
Origin & History

Cannabigerol (CBG) is a minor cannabinoid found in the cannabis plant, often extracted from young plants where it is more abundant. It is typically obtained using CO2 extraction methods.
Research Narrative (Provisional)
Preliminary studies, including in vitro and animal research, suggest potential benefits in neuroprotection and inflammation. Human trials are limited but ongoing.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
- Contains cannabinoids that interact with the endocannabinoid system. - Non-psychoactive and found in small quantities in cannabis. - Often used in combination with other cannabinoids for enhanced effects.
Reported Mechanism (Provisional)
CBG acts as a weak partial agonist of CB1 and CB2 cannabinoid receptors while antagonizing α2-adrenergic receptors and activating TRPM8 channels. It inhibits the reuptake of anandamide and modulates adenosine A2A receptors, contributing to its neuroprotective effects. CBG also interacts with 5-HT1A serotonin receptors and blocks calcium channels, which underlies its anti-inflammatory and analgesic properties.
Clinical Narrative (Provisional)
Human clinical research on CBG remains limited, with most evidence derived from preclinical studies and animal models. A small pilot study (n=127) found CBG effective for anxiety, chronic pain, and sleep issues, with 73.9% reporting improved sleep quality. Animal studies demonstrate significant neuroprotective effects in Huntington's disease models and inflammatory bowel disease, with dosages ranging from 1-10 mg/kg showing efficacy. Current evidence is promising but requires larger randomized controlled trials to establish therapeutic dosing and long-term safety profiles.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.







